

UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

Page 1

Atty. Docket No. 12441.00002

Assistant Commissioner of Patents
Box Patent Applications
Washington, D.C. 20231

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): MICHAEL A. INNIS

Title of Invention: PRODUCTION OF TISSUE FACTOR PATHWAY INHIBITOR

- ☒ Continuation
☐ Divisional
☐ Continuation-in-Part

of prior application No. 08/854,764, filed May 12, 1997

1. ☒ Specification 31 pages (including specification, claims, abstract) / 11 claims (1 independent)
2. ☒ Declaration/Power of Attorney:
 - ☒ Copy from Prior Application (for continuation or divisional application)
 - ☐ Newly Executed Declaration (for CIP application)
 - ☐ Deferred under 37 C.F.R. § 1.53(f)
 - ☐ Deletion of Inventor(s) - Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b)
 - ☒ Incorporation by Reference - The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein
3. ☒ 4 Distinct sheets of ☒ Formal ☐ Informal Drawings
4. ☐ Preliminary Amendment
5. ☐ Information Disclosure Statement
 - ☐ Form 1449
 - ☐ A copy of each cited prior art reference
6. ☒ Assignment
 - ☐ Assignment with Cover Sheet attached
 - ☒ Assignment filed in prior application. Application assigned to: **Chiron Corporation**
7. ☒ Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):

08/15/00
JC862 U.S. PTO
09/639273

JC862 U.S. PTO
09/639273
08/15/00

UNITED STATES CONTINUING UTILITY PATENT APPLICATION

under 37 C.F.R. § 1.53(b)

Page 2

Atty. Docket No. 12441.00002

Country	Application Number	Date of Filing (day, month, year)
US	08/854,764	12 May 1997
US	08/286,530	05 August 1994

8. ☐ Priority Document(s)
- ☐ was filed in prior application
- ☐ is attached
- ☐ will be submitted prior to or concurrently with the payment of any issue fee for the instant application

9. ☐ Small Entity Statement
- ☐ Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
- ☐ is attached
- ☐ is no longer claimed

10. ☐ Microfiche Computer Program (Appendix)

11. ☐ Nucleotide and/or Amino Acid Sequence Submission
- ☐ Computer Readable Copy
- ☐ Paper Copy (identical to computer copy)
- ☐ Statement verifying identity of above copies

12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$690.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	0	18.00	\$360.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	0	78.00	\$234.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	260.00	\$2,600.00
Subtotal - Filing Fee Due			\$3,884.00
	MULTIPLY BY		
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0		\$1,942.00
TOTAL FILING FEE DUE			\$1,942.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$400.00
GRAND TOTAL DUE			\$2,342.00

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Page 3

Atty. Docket No. 12441.00002

13. PAYMENT is:


- ☐ included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing and for any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18
- ☒ not included, but deferred under 37 C.F.R. § 1.53(f).

14. All correspondence for the attached application should be directed to:

Banner & Witcoff, Ltd.
1001 G Street, N.W.
Washington, D. C. 20001-4597
Telephone: (202) 508-9100
Facsimile: (202) 508-9299

15. Other: _____

Date: August 15, 2000

By: 

Sarah A. Kagan
Reg. No. 32,141

SAK/ama